Matinas Biopharma, Inc.
Matinas Biopharma, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for serious diseases. Founded in 2013, Matinas has made significant strides in the biotechnology sector, particularly in the areas of lipid-based drug delivery systems and oral formulations. The company’s flagship product, MAT2203, is a unique oral formulation of amphotericin B, designed to treat fungal infections with improved safety and efficacy. Matinas Biopharma stands out in the industry for its proprietary lipid nanocrystal technology, which enhances drug solubility and bioavailability. With a strong commitment to advancing healthcare solutions, Matinas has positioned itself as a leader in the biopharma landscape, achieving notable milestones in clinical development and partnerships that underscore its potential for growth and innovation.
DitchCarbon Score
How does Matinas Biopharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Matinas Biopharma, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Matinas Biopharma, Inc.'s reported carbon emissions
Matinas Biopharma, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of detailed information, it is essential to monitor their future disclosures for any developments regarding their climate commitments and sustainability practices.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Matinas Biopharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
